Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Dario Mirski"'
Publikováno v:
Community Mental Health Journal. 49:625-629
Nonadherence to antipsychotic medications is widespread and compromises the outcome of patients with schizophrenia. Using the MarketScan Medicare claims database, this study examined the impact of medication adherence on healthcare utilization among
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::349bd07f5db027c25fa69dfde81f73d9
https://doi.org/10.1007/s10597-013-9638-y
https://doi.org/10.1007/s10597-013-9638-y
Publikováno v:
Advances in Therapy. 30:286-297
To quantify early nonadherence to antipsychotic medications in patients with schizophrenia and its impact on short-term antipsychotic adherence, healthcare utilization, and costs.Patients who initiated oral antipsychotic treatment between January 1,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9cd5bc8ac045e30dc0e17a57e881142
https://doi.org/10.1007/s12325-013-0016-5
https://doi.org/10.1007/s12325-013-0016-5
Autor:
Barbara Koumaras, Dario Mirski, Michael Chen, Jonathan M. Silver, Philip D. Harvey, David B. Arciniegas, Patricio F. Reyes, Ibrahim Gunay, Steven G. Potkin, D. Warden, Douglas I. Katz
Publikováno v:
Neurology. 67:748-755
Objective: To compare the efficacy and safety of rivastigmine (3 to 6 mg/day) vs placebo over 12 weeks in patients with traumatic brain injury and persistent cognitive impairment. Methods: This prospective, randomized, double-blind, placebo-controlle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff27e7b662b45ed3627581c02847113f
https://doi.org/10.1212/01.wnl.0000234062.98062.e9
https://doi.org/10.1212/01.wnl.0000234062.98062.e9
Publikováno v:
Drugs & Aging. 23:241-249
The two most common causes of dementia in the elderly are Alzheimer's disease (AD) and vascular dementia (VaD), which can coexist as mixed dementia. The object of this study was to assess the efficacy and safety of rivastigmine in patients with mixed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc0a962f2491a20c89767fae1950447b
https://doi.org/10.2165/00002512-200623030-00006
https://doi.org/10.2165/00002512-200623030-00006
Autor:
Patrick J Moriarty, Dario Mirski, Michael Chen, Philip D. Harvey, Leah Kleinman, Karin Coyne, Carl H. Sadowsky
Publikováno v:
Alzheimer Disease & Associated Disorders. 19:186-194
Objective: The objective of this study was to refine and validate the Dementia Severity Scale (DSS), a newly developed assessment of dementia severity from a caregiver's perspective. The Dementia Severity Scale is designed to measure deficits in acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec6fe48956ca303ae313bbca0f5df051
https://doi.org/10.1097/01.wad.0000189034.43203.60
https://doi.org/10.1097/01.wad.0000189034.43203.60
Publikováno v:
Journal of the American Medical Directors Association. 6:238-245
Objectives The Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) was used to study the impact of rivastigmine (Exelon; Novartis Pharmaceuticals Corporation, East Hanover, NJ), on occupational disruptiveness (OD), a proxy measure for profession
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e10b597dd30ab0cd54bb44b02a380cf
https://doi.org/10.1016/j.jamda.2005.04.003
https://doi.org/10.1016/j.jamda.2005.04.003
Publikováno v:
Clinical Drug Investigation. 25:507-515
Neuropsychiatric symptoms and behavioural disturbances occur in most patients with Alzheimer's disease (AD), are a source of stress for caregivers, and are the primary cause of patient institutionalisation. These symptoms often are treated with psych
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae821452c558c3f86727beb6d135b5ba
https://doi.org/10.2165/00044011-200525080-00003
https://doi.org/10.2165/00044011-200525080-00003
Publikováno v:
Current Medical Research and Opinion. 20:1605-1612
To evaluate the safety and efficacy of long-term treatment with rivastigmine (3-12 mg/day) and its effects on neuropsychiatric and behavioral disturbances in nursing home patients with moderate to severe probable Alzheimer's disease (AD).A prospectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0baf951fa60e535e4710ab9eb4422c2c
https://doi.org/10.1185/030079904125004204
https://doi.org/10.1185/030079904125004204
Autor:
Dario Mirski, Adrian L. Rabinowicz, Christopher Powers, Dong-Churl Suh, Simu K. Thomas, Hyunchul Shin, Stephen Arcona
Publikováno v:
Drugs & Aging. 21:395-403
Background and Objective: Cholinesterase inhibitors may offer some improvement in the behavioural symptoms of Alzheimer’s disease. The dual inhibitory mechanism of action of rivastigmine (inhibition of acetylcholinesterase and butyrylcholinesterase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8ad436a1fbe62a8868da9eba7ad0a72
https://doi.org/10.2165/00002512-200421060-00004
https://doi.org/10.2165/00002512-200421060-00004
Publikováno v:
The journal of behavioral health servicesresearch. 40(3)
Real-world medication adherence and healthcare costs of patients with schizophrenia initiating long-acting injectable (LAI) vs. oral antipsychotics were compared. Patients with schizophrenia initiating LAI or oral antipsychotics (index event) were id
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::792e6d6ca5f6ea26eb8de40d691f59c8
https://pubmed.ncbi.nlm.nih.gov/23579871
https://pubmed.ncbi.nlm.nih.gov/23579871